Table 1.
Patient characteristics of treatment-naïve pediatric IBD cohort
| Controls (n = 24) | CD (n = 25) | UC (n = 22) | |
|---|---|---|---|
| Gender | |||
| Male/female | 10/14 | 16/9 | 11/11 |
| Age | |||
| Median (Q1–Q3) | 15.0 (13.5–16.3) | 13.8 (12.3–16.1) | 14.9 (11.2–16.2) |
| Disease activity | |||
| Severe/moderate/mild | NA | (13/6/6) | (5/14/3) |
| Paris classification | |||
| A1a/A1b/A2 | NA | (4/19/2) | NA |
| L1/L2/L3/L4a/L4b | NA | (3/4/16/12/4) | NA |
| B1/B2/B3/p | NA | (23/1/1/4) | NA |
| G0/G1 | NA | (17/8) | NA |
| E1/E2/E3/E4 | NA | NA | (1/3/4/14) |
| S0/S1 | NA | NA | (14/8) |
| MLI aspirate samples (inflammatory status) |
|||
| DeC (w/o inflam/w inflam) | 20/0 | 11/9 | 17/1 |
| AsC (w/o inflam/w inflam) | 22/0 | 11/11 | 12/6 |
| TI (w/o inflam/w inflam) | 21/0 | 16/3 | 16/0 |